Lipoamide (BioDeep_00000003137)
Secondary id: BioDeep_00000399999
natural product human metabolite PANOMIX_OTCML-2023 Endogenous BioNovoGene_Lab2019
代谢物信息卡片
5-(1,2-Dithiolan-3-yl)-pentanamide
化学式: C8H15NOS2 (205.0595)
中文名称: 硫辛酰胺, (±)-α-硫辛酰胺
谱图信息:
最多检出来源 Homo sapiens(plant) 5.57%
分子结构信息
SMILES: C(CCC(=O)N)CC1CCSS1
InChI: InChI=1S/C8H15NOS2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H2,9,10)
描述信息
Lipoamide is a trivial name for 6,8-dithiooctanoic amide. It is 6,8-dithiooctanoic acids functional form where the carboxyl group is attached to protein (or any other amine) by an amide linkage (containing -NH2) to an amino group. Lipoamide forms a thioester bond, oxidizing the disulfide bond, with acetaldehyde (pyruvate after it has been decarboxylated). It then transfers the acetaldehyde group to CoA which can then continue in the TCA cycle. Lipoamide is an intermediate in glycolysis/gluconeogenesis, citrate cycle (TCA cycle), alanine, aspartate and pyruvate metabolism, and valine, leucine and isoleucine degradation (KEGG:C00248). It is generated from dihydrolipoamide via the enzyme dihydrolipoamide dehydrogenase (EC:1.8.1.4) and then converted to S-glutaryl-dihydrolipoamide via the enzyme oxoglutarate dehydrogenase (EC:1.2.4.2).
Lipoamide is the oxidized form of glutathione. (PMID:8957191)
KEIO_ID L031; [MS2] KO009031
KEIO_ID L031
同义名列表
40 个代谢物同义名
5-(1,2-Dithiolan-3-yl)-pentanamide; 5-(1,2-dithiolan-3-yl)pentanamide; 5-(1,2-Dithiolan-3-yl)valeramide; 5-(Dithiolan-3-yl)valeramide; 1,2-Dithiolane-3-pentanamide; 1,2-Dithiolane-3-valeramide; alpha-lipoic acid amide; Lipoamide, (+-)-isomer; (+/-)-alpha-Lipoamide; a-Lipoic acid amide; DL-6-Thioctic amide; Α-lipoic acid amide; alpha-Lipoate amide; Thioctic acid amide; alpha-Lipoic amide; 6,8-Thioctic amide; alpha-Lipoic acid; Α-lipoate amide; a-Lipoate amide; Thioctate amide; DL-Thioctamide; alpha-Lipoate; DL-Lipoamide; Thioctamide; a-Lipoamide; Thioctamid; Thiotomin; Pathoclon; lipoamide; vitamin N; Lipoicin; Lipozyme; Lipamide; Lipoacin; Lipoamid; Lypoaran; Ticolin; Thioami; Lipoamide; Lipoamide
数据库引用编号
33 个数据库交叉引用编号
- ChEBI: CHEBI:17460
- KEGG: C00248
- KEGGdrug: D92402
- KEGGdrug: D00048
- PubChem: 3547
- PubChem: 863
- HMDB: HMDB0000962
- Metlin: METLIN3372
- ChEMBL: CHEMBL1403899
- Wikipedia: Lipoamide
- MetaCyc: LIPOAMIDE
- foodb: FDB022340
- chemspider: 840
- CAS: 3206-73-3
- CAS: 940-69-2
- MoNA: KO003314
- MoNA: KO009032
- MoNA: KO009031
- MoNA: PS021502
- MoNA: KO003316
- MoNA: PS062701
- MoNA: PS062702
- MoNA: KO003312
- MoNA: KO003313
- MoNA: PS021501
- MoNA: KO009033
- MoNA: KO003315
- PMhub: MS000008229
- LipidMAPS: LMFA08010006
- NIKKAJI: J25.390A
- RefMet: Lipoamide
- BioNovoGene_Lab2019: BioNovoGene_Lab2019-440
- KNApSAcK: 17460
分类词条
相关代谢途径
Reactome(7)
PlantCyc(0)
代谢反应
399 个相关的代谢反应过程信息。
Reactome(0)
WikiPathways(0)
Plant Reactome(320)
- Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + SACN ⟶ L-Glu + NADH + allysine - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
H2O + L-Asn ⟶ L-Asp + ammonia - Lysine degradation II:
LIPAM + aKADA ⟶ S-glutaryldihydrolipoamide + carbon dioxide - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
2OG + L-Lys + TPNH ⟶ H2O + SACN + TPN - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
L-Glu + imidazole acetol-phosphate ⟶ 2OG + L-histidinol-phosphate - Amino acid metabolism:
L-Glu + imidazole acetol-phosphate ⟶ 2OG + L-histidinol-phosphate - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + SACN ⟶ L-Glu + NADH + allysine - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
2OG + L-Val ⟶ Glu + KIV - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
2OG + L-Lys + TPNH ⟶ H2O + SACN + TPN - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
H2O + L-Asn ⟶ L-Asp + ammonia - Lysine degradation II:
LIPAM + aKADA ⟶ S-glutaryldihydrolipoamide + carbon dioxide - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
H2O + L-Asn ⟶ L-Asp + ammonia - Lysine degradation II:
LIPAM + aKADA ⟶ S-glutaryldihydrolipoamide + carbon dioxide - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
L-Glu + imidazole acetol-phosphate ⟶ 2OG + L-histidinol-phosphate - Amino acid metabolism:
L-Glu + imidazole acetol-phosphate ⟶ 2OG + L-histidinol-phosphate - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + SACN ⟶ L-Glu + NADH + allysine - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
2OG + L-Lys + TPNH ⟶ H2O + SACN + TPN - Metabolism and regulation:
L-Glu + imidazole acetol-phosphate ⟶ 2OG + L-histidinol-phosphate - Amino acid metabolism:
L-Glu + imidazole acetol-phosphate ⟶ 2OG + L-histidinol-phosphate - Amino acid catabolism:
2OG + L-Val ⟶ Glu + KIV - Lysine degradation II:
H2O + NAD + SACN ⟶ L-Glu + NADH + allysine - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
2OG + L-Lys + TPNH ⟶ H2O + SACN + TPN - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
2OG + L-Lys + TPNH ⟶ H2O + SACN + TPN - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
2OG + L-Lys + TPNH ⟶ H2O + SACN + TPN - Metabolism and regulation:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid metabolism:
FAD + PROP-CoA ⟶ FADH2 + acryloyl-CoA - Amino acid catabolism:
CoA + KIV + NAD ⟶ ISB-CoA + NADH + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
ATP + CoA + propionate ⟶ AMP + PPi + PROP-CoA - Amino acid metabolism:
ATP + CoA + propionate ⟶ AMP + PPi + PROP-CoA - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate - Metabolism and regulation:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid metabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Amino acid catabolism:
CoA + NAD + methylmalonate-semialdehyde ⟶ NADH + PROP-CoA + carbon dioxide - Lysine degradation II:
H2O + NAD + allysine ⟶ NADH + alpha-aminoadipate
INOH(5)
- Pyruvate metabolism ( Pyruvate metabolism ):
ATP + Acetic acid + CoA ⟶ AMP + Acetyl-CoA + Pyrophosphate - Pyruvic acid + Enzyme N6-(lipoyl)lysine = [dihydrolipoyllysine-residue acetyltransferase] S-acetyldihydrolipoyllysine + CO2 ( Pyruvate metabolism ):
Pyruvic acid + TPP ⟶ 2-(Hydroxyethyl)-thiamine diphosphate + CO2 - Citrate cycle ( Citrate cycle ):
H2O + cis-Aconitic acid ⟶ Isocitric acid - 2-oxoglutarate + [dihydrolipoyllysine-residue succinyltransferase] lipoyllysine = [dihydrolipoyllysine-residue succinyltransferase] S-succinyldihydrolipoyllysine + CO2 ( Citrate cycle ):
2-Oxo-glutaric acid + TPP ⟶ 3-Carboxy-1-hydroxypropyl-ThPP + CO2 - NAD+ + Dihydro-lipoamide = NADH + Lipoamide ( Pyruvate metabolism ):
Lipoamide + NADH ⟶ Dihydro-lipoamide + NAD+
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(73)
- Pyruvate Metabolism:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Leigh Syndrome:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency):
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Pyruvate Dehydrogenase Complex Deficiency:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Primary Hyperoxaluria II, PH2:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Pyruvate Kinase Deficiency:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Pyruvate Metabolism:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Leigh Syndrome:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Dehydrogenase Complex Deficiency:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency):
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Primary Hyperoxaluria II, PH2:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Kinase Deficiency:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Metabolism:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Metabolism:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Metabolism:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Pyruvate Metabolism:
Acetic acid + Coenzyme A ⟶ Acetyl-CoA + Water - Leigh Syndrome:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Dehydrogenase Complex Deficiency:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency):
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Primary Hyperoxaluria II, PH2:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Pyruvate Kinase Deficiency:
Acetaldehyde + NAD + Water ⟶ Acetic acid + Hydrogen Ion + NADH - Valine, Leucine, and Isoleucine Degradation:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - beta-Ketothiolase Deficiency:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 2-Methyl-3-hydroxybutyryl-CoA Dehydrogenase Deficiency:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Propionic Acidemia:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Maple Syrup Urine Disease:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Methylglutaconic Aciduria Type I:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Methylglutaconic Aciduria Type III:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Methylmalonate Semialdehyde Dehydrogenase Deficiency:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Methylmalonic Aciduria:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Isovaleric Aciduria:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Methylglutaconic Aciduria Type IV:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Hydroxyisobutyric Acid Dehydrogenase Deficiency:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - 3-Hydroxyisobutyric Aciduria:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Isobutyryl-CoA Dehydrogenase Deficiency:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Isovaleric Acidemia:
-Ketoisovaleric acid + Thiamine pyrophosphate ⟶ 2-Methyl-1-hydroxypropyl-ThPP + Carbon dioxide - Valine, Leucine, and Isoleucine Degradation:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylglutaconic Aciduria Type I:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylglutaconic Aciduria Type III:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylglutaconic Aciduria Type IV:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - beta-Ketothiolase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Isovaleric Aciduria:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Maple Syrup Urine Disease:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Methylmalonate Semialdehyde Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Methylmalonic Aciduria:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Propionic Acidemia:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Hydroxyisobutyric Acid Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Hydroxyisobutyric Aciduria:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Isobutyryl-CoA Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Isovaleric Acidemia:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Valine, Leucine, and Isoleucine Degradation:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Valine, Leucine, and Isoleucine Degradation:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Hydroxy-3-methylglutaryl-CoA Lyase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylcrotonyl-CoA Carboxylase Deficiency Type I:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylglutaconic Aciduria Type I:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylglutaconic Aciduria Type III:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Methylglutaconic Aciduria Type IV:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - beta-Ketothiolase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Isovaleric Aciduria:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Maple Syrup Urine Disease:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Methylmalonate Semialdehyde Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Methylmalonic Aciduria:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Propionic Acidemia:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Hydroxyisobutyric Acid Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - 3-Hydroxyisobutyric Aciduria:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Isobutyryl-CoA Dehydrogenase Deficiency:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid - Isovaleric Acidemia:
L-Valine + Oxoglutaric acid ⟶ -Ketoisovaleric acid + L-Glutamic acid
PharmGKB(0)
3 个相关的物种来源信息
- 7461 - Apis cerana: 10.1371/JOURNAL.PONE.0175573
- 9606 - Homo sapiens:
- 9606 - Homo sapiens: -
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Guo-Guo Chu, Jing Wang, Zhi-Bin Ding, Jin-Zhu Yin, Li-Juan Song, Qing Wang, Jian-Jun Huang, Bao-Guo Xiao, Cun-Gen Ma. Hydroxyfasudil regulates immune balance and suppresses inflammatory responses in the treatment of experimental autoimmune encephalomyelitis.
International immunopharmacology.
2023 Aug; 124(Pt A):110791. doi:
10.1016/j.intimp.2023.110791. [PMID: 37619413] - Shan Hua, Fei Shi, Zhiwen Xie, Lei Wu, Mengqiao Dai, Yongqing Zhang, Xinyu Xu, Yiping Zhu, Juntao Jiang. Di-n-butyl phthalate induces oversecretion of vascular endothelium-derived NAP-2 and promotes epithelial-mesenchymal transition of urothelial cells in newborn hypospadias rats.
Ecotoxicology and environmental safety.
2023 May; 256(?):114892. doi:
10.1016/j.ecoenv.2023.114892. [PMID: 37059017] - Min-Fang Guo, Hui-Yu Zhang, Pei-Jun Zhang, Yi-Jin Zhao, Jing-Wen Yu, Tao Meng, Meng-Di Li, Na Li, Cun-Gen Ma, Li-Juan Song, Jie-Zhong Yu. Fasudil alleviates cerebral ischemia‑reperfusion injury by inhibiting inflammation and improving neurotrophic factor expression in rats.
Acta neurobiologiae experimentalis.
2023; 83(1):97-110. doi:
10.55782/ane-2023-010. [PMID: 37078818] - Huiying Zhao, Xintong Li, Yongqi Zheng, Xiaofeng Zhu, Xunzhong Qi, Xinyan Huang, Shunjie Bai, Chengji Wu, Guangtao Sun. Fasudil may alleviate alcohol-induced astrocyte damage by modifying lipid metabolism, as determined by metabonomics analysis.
PeerJ.
2023; 11(?):e15494. doi:
10.7717/peerj.15494. [PMID: 37304877] - H A Elkattawy, D Ma Elsherbini, H A Ebrahim, D M Abdullah, S A Al-Zahaby, Y Noser, A E-S Hassan. Rho-kinase inhibition ameliorates non-alcoholic fatty liver disease in type 2 diabetic rats.
Physiological research.
2022 11; 71(5):615-630. doi:
10.33549/physiolres.934869. [PMID: 36047723] - Minfang Guo, Huiyu Zhang, Jingwen Yu, Peijun Zhang, Yuyin Wang, Wenyue Wei, Lijuan Song, Zhi Chai, Jiezhong Yu, Cungen Ma. [Fasudil reduces apoptosis of SH-SY5Y cells induced by H2O2 and promotes synaptic plasticity by inhibiting neurite outgrowth inhibitor A and its receptor (NogoA/NgR) signaling pathway].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2022 Jul; 38(7):625-631. doi:
. [PMID: 35786457] - Di Chen, Tianyi Yuan, Yucai Chen, Huifang Zhang, Ziran Niu, Lianhua Fang, Guanhua Du. DL0805-1, a novel Rho-kinase inhibitor, attenuates lung injury and vasculopathy in a rat model of monocrotaline-induced pulmonary hypertension.
European journal of pharmacology.
2022 Mar; 919(?):174779. doi:
10.1016/j.ejphar.2022.174779. [PMID: 35092757] - Jinghui Liang, Mu Tang, Lieliang Wang, Rui Huang, Ailong Fu, Juying Zhou. Design and development of novel fasudil derivatives as potent antibreast cancer agent that improves intestinal flora and intestinal barrier function in rats.
Chemical biology & drug design.
2021 12; 98(6):1065-1078. doi:
10.1111/cbdd.13963. [PMID: 34587363] - Yingchun Xiang, Yumiao Niu, Yacong Xie, Shishuo Chen, Feng Zhu, Weida Shen, Ling-Hui Zeng. Inhibition of RhoA/Rho kinase signaling pathway by fasudil protects against kainic acid-induced neurite injury.
Brain and behavior.
2021 08; 11(8):e2266. doi:
10.1002/brb3.2266. [PMID: 34156163] - Taslim A Al-Hilal, Mohammad Anwar Hossain, Ahmed Alobaida, Farzana Alam, Ali Keshavarz, Eva Nozik-Grayck, Kurt R Stenmark, Nadezhda A German, Fakhrul Ahsan. Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects.
Journal of controlled release : official journal of the Controlled Release Society.
2021 06; 334(?):237-247. doi:
10.1016/j.jconrel.2021.04.030. [PMID: 33915222] - Zhi-Bin Ding, Qing-Xian Han, Qing Wang, Li-Juan Song, Guo-Guo Chu, Min-Fang Guo, Zhi Chai, Jie-Zhong Yu, Bao-Guo Xiao, Xin-Yi Li, Cun-Gen Ma. Fasudil enhances the phagocytosis of myelin debris and the expression of neurotrophic factors in cuprizone-induced demyelinating mice.
Neuroscience letters.
2021 05; 753(?):135880. doi:
10.1016/j.neulet.2021.135880. [PMID: 33838256] - Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
Cell reports.
2021 04; 35(4):109040. doi:
10.1016/j.celrep.2021.109040. [PMID: 33910017] - Jie Yang, Qingzheng Zhu, Feng Xu, Ming Yang, Hechao Du, Xiaoying Bian, Zhaoxin Lu, Yingjian Lu, Fengxia Lu. Genome Mining, Heterologous Expression, Antibacterial and Antioxidant Activities of Lipoamides and Amicoumacins from Compost-Associated Bacillus subtilis fmb60.
Molecules (Basel, Switzerland).
2021 Mar; 26(7):. doi:
10.3390/molecules26071892. [PMID: 33810551] - Xiwen Ren, Tong Meng, Xingbin Ren, Xiaoyu Li, Lin Lu. Fasudil alleviates acetaminophen-induced liver injury via targeting Rhoa/ROCK signal pathway.
The Journal of toxicological sciences.
2021; 46(6):255-262. doi:
10.2131/jts.46.255. [PMID: 34078832] - Wenyue Wei, Yuyin Wang, Jing Zhang, Qingfang Gu, Xiaoqin Liu, Lijuan Song, Zhi Chai, Minfang Guo, Jiezhong Yu, Cungen Ma. Fasudil ameliorates cognitive deficits, oxidative stress and neuronal apoptosis via inhibiting ROCK/MAPK and activating Nrf2 signalling pathways in APP/PS1 mice.
Folia neuropathologica.
2021; 59(1):32-49. doi:
10.5114/fn.2021.105130. [PMID: 33969676] - Chengyu Xiang, Yi Yan, Dingguo Zhang. Alleviation of the doxorubicin-induced nephrotoxicity by fasudil in vivo and in vitro.
Journal of pharmacological sciences.
2021 Jan; 145(1):6-15. doi:
10.1016/j.jphs.2020.10.002. [PMID: 33357780] - Min-Fang Guo, Hui-Yu Zhang, Pei-Jun Zhang, Xiao-Qin Liu, Li-Juan Song, Wen-Yue Wei, Yu-Yin Wang, Bing-Tao Mu, Zhi Chai, Jie-Zhong Yu, Cun-Gen Ma. Fasudil reduces β-amyloid levels and neuronal apoptosis in APP/PS1 transgenic mice via inhibition of the Nogo-A/NgR/RhoA signaling axis.
Journal of integrative neuroscience.
2020 Dec; 19(4):651-662. doi:
10.31083/j.jin.2020.04.243. [PMID: 33378839] - Yosuke Yanagida, Mio Namba, Tatsuya Fukuta, Hirokazu Yamamoto, Mitsuaki Yanagida, Miki Honda, Naoto Oku, Tomohiro Asai. Release rate is a key variable affecting the therapeutic effectiveness of liposomal fasudil for the treatment of cerebral ischemia/reperfusion injury.
Biochemical and biophysical research communications.
2020 10; 531(4):622-627. doi:
10.1016/j.bbrc.2020.07.038. [PMID: 32819716] - Yi Yan, Chengyu Xiang, Zhijian Yang, Dengshun Miao, Dingguo Zhang. Rho Kinase Inhibition by Fasudil Attenuates Adriamycin-Induced Chronic Heart Injury.
Cardiovascular toxicology.
2020 08; 20(4):351-360. doi:
10.1007/s12012-019-09561-6. [PMID: 31894538] - Sizhe Wan, Fangyun Luo, Chenkai Huang, Cong Liu, Qingtian Luo, Xuan Zhu. Ursolic acid reverses liver fibrosis by inhibiting interactive NOX4/ROS and RhoA/ROCK1 signalling pathways.
Aging.
2020 06; 12(11):10614-10632. doi:
10.18632/aging.103282. [PMID: 32496208] - Wenjun Liu, Jing Gao, Xiulin Yi, Yazhuo Li, Yong Zeng. Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs.
Biopharmaceutics & drug disposition.
2020 Apr; 41(4-5):206-220. doi:
10.1002/bdd.2231. [PMID: 32383777] - Meihui Chen, Dan Luo, Jiheng Zhan, Yu Hou, Shudong Chen, Xing Li, Dingkun Lin. Fasudil enhanced differentiation of BMSCs in vivo and vitro, involvement of P38 signaling pathway.
Chemico-biological interactions.
2020 Feb; 317(?):108944. doi:
10.1016/j.cbi.2020.108944. [PMID: 31935364] - Fajiang Xie, Jiesen Lei, Maoxia Ran, Yan Li, Li Deng, Jian Feng, Yi Zhong, Jiafu Li. Attenuation of Diabetic Nephropathy in Diabetic Mice by Fasudil through Regulation of Macrophage Polarization.
Journal of diabetes research.
2020; 2020(?):4126913. doi:
10.1155/2020/4126913. [PMID: 32685556] - Cecília R Panta, Éva Ruisanchez, Dorottya Móré, Péter T Dancs, Andrea Balogh, Ágnes Fülöp, Margit Kerék, Richard L Proia, Stefan Offermanns, Gábor J Tigyi, Zoltán Benyó. Sphingosine-1-Phosphate Enhances α1-Adrenergic Vasoconstriction via S1P2-G12/13-ROCK Mediated Signaling.
International journal of molecular sciences.
2019 Dec; 20(24):. doi:
10.3390/ijms20246361. [PMID: 31861195] - Ye Gao, Yuqing Yan, Qingli Fang, Nianping Zhang, Gajendra Kumar, Jihong Zhang, Li-Juan Song, Jiezhong Yu, Linhu Zhao, Han-Ting Zhang, Cun-Gen Ma. The Rho kinase inhibitor fasudil attenuates Aβ1-42-induced apoptosis via the ASK1/JNK signal pathway in primary cultures of hippocampal neurons.
Metabolic brain disease.
2019 12; 34(6):1787-1801. doi:
10.1007/s11011-019-00487-0. [PMID: 31482248] - Demeng Xia, Xueli Lai, Kaiwen Wu, Panyu Zhou, Lei Li, Zhiyong Guo, Shuogui Xu. Metabolomics study of fasudil on cisplatin-induced kidney injury.
Bioscience reports.
2019 11; 39(11):. doi:
10.1042/bsr20192940. [PMID: 31670380] - Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology.
2019 11; 96(5):629-640. doi:
10.1124/mol.119.115964. [PMID: 31515284] - Gonzalo I Gómez, Victoria Velarde, Juan C Sáez. Role of a RhoA/ROCK-Dependent Pathway on Renal Connexin43 Regulation in the Angiotensin II-Induced Renal Damage.
International journal of molecular sciences.
2019 Sep; 20(18):. doi:
10.3390/ijms20184408. [PMID: 31500276] - Li Wang, Jianghua Xu, Dadong Guo, Xudong Zhou, Wenwen Jiang, Jinglin Wang, Jiyou Tang, Yong Zou, Mingjun Bi, Qin Li. Fasudil alleviates brain damage in rats after carbon monoxide poisoning through regulating neurite outgrowth inhibitor/oligodendrocytemyelin glycoprotein signalling pathway.
Basic & clinical pharmacology & toxicology.
2019 Aug; 125(2):152-165. doi:
10.1111/bcpt.13233. [PMID: 30916885] - Shang-De Guo, Chun-Yun Liu, Jing-Wen Yu, Zhi Chai, Qing Wang, Xi-Ting Mi, Guo-Bin Song, Yan-Hua Li, Peng-Wei Yang, Ling Feng, Bao-Guo Xiao, Cun-Gen Ma. Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis.
CNS neuroscience & therapeutics.
2019 06; 25(6):783-795. doi:
10.1111/cns.13111. [PMID: 30779332] - Xue-Ying Wang, Dan Mo, Wen Tian, Xiao-Xiao Liu, Ya-Guang Zhou, Yang Sun, Ying-Da Feng, Xiong Xiao, Xiao-Wei Hao, Hui-Nan Zhang, Chen Li, Wei Cao, Xiao-Qiang Li. Inhibition of RhoA/ROCK signaling pathway ameliorates hypoxic pulmonary hypertension via HIF-1α-dependent functional TRPC channels.
Toxicology and applied pharmacology.
2019 04; 369(?):60-72. doi:
10.1016/j.taap.2019.02.017. [PMID: 30831131] - Xinpeng Yan, Kai Jiao, Xiaozheng Song. Shen'ge powder decreases the cardiomyocyte hypertrophy in chronic heart failure by activating the Rho protein/Rho-associated coiledcoil forming protein kinase signaling pathway.
Journal of cellular biochemistry.
2019 03; 120(3):3038-3045. doi:
10.1002/jcb.27386. [PMID: 30474257] - Jiansong Fang, Chuipu Cai, Yanting Chai, Jingwei Zhou, Yujie Huang, Li Gao, Qi Wang, Feixiong Cheng. Quantitative and systems pharmacology 4. Network-based analysis of drug pleiotropy on coronary artery disease.
European journal of medicinal chemistry.
2019 Jan; 161(?):192-204. doi:
10.1016/j.ejmech.2018.10.020. [PMID: 30359818] - Kezhi Dai, Yaoyao Wang, Sichao Tai, Huajing Ni, Hao Lian, Yan Yu, Weifang Liao, Cheng Zheng, Qing Chen, Aarti Kuver, Jia Li. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
Cardiovascular therapeutics.
2018 Dec; 36(6):e12477. doi:
10.1111/1755-5922.12477. [PMID: 30380183] - Shawn F L Hanson, Michael H Terry, Dafne T Moretta, Gordon G Power, Sean M Wilson, Farzana Alam, Fakhrul Ahsan, Arlin B Blood, Paresh C Giri. Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs.
Journal of cardiovascular pharmacology and therapeutics.
2018 09; 23(5):472-480. doi:
10.1177/1074248418772814. [PMID: 29756460] - Jing Fu, Li Chang. Fabrication of fasudil hydrochloride modified graphene oxide biocomposites and its defensive effect acute renal injury in septicopyemia rats.
Journal of photochemistry and photobiology. B, Biology.
2018 Sep; 186(?):125-130. doi:
10.1016/j.jphotobiol.2018.07.005. [PMID: 30036829] - Can Peng, Xiaohan Jiang, Ying Xiao, Zhiping Yuan, Yanwen Mao, Yuanyuan Wang Wang, Yingying Zhang, Fan Zhang, Lei Tang, Bing Guo. [Alpha-lipoamide inhibits renal inflammation and collagen 4 production in diabetic rats and its mechanism].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2018 Jul; 34(7):617-622. doi:
. [PMID: 30381126] - Cheng Li, Ping-Ping Liu, Dou-Dou Tang, Rong Song, Yi-Qing Zhang, Si Lei, Shang-Jie Wu. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension.
Pulmonary pharmacology & therapeutics.
2018 06; 50(?):111-122. doi:
10.1016/j.pupt.2018.04.004. [PMID: 29673911] - Duy Trong Vien Diep, Kyungki Hong, Triyeng Khun, Mei Zheng, Asad Ul-Haq, Hee-Sook Jun, Young-Bum Kim, Kwang-Hoon Chun. Anti-adipogenic effects of KD025 (SLx-2119), a ROCK2-specific inhibitor, in 3T3-L1 cells.
Scientific reports.
2018 02; 8(1):2477. doi:
10.1038/s41598-018-20821-3. [PMID: 29410516] - Solomon L Woldu, Ryan C Hutchinson, Laura-Maria Krabbe, Oner Sanli, Vitaly Margulis. The Rho GTPase signalling pathway in urothelial carcinoma.
Nature reviews. Urology.
2018 02; 15(2):83-91. doi:
10.1038/nrurol.2017.184. [PMID: 29133936] - Yiming Wang, Hao Zhang, Zhijian Yang, Dengshun Miao, Dingguo Zhang. Rho Kinase Inhibitor, Fasudil, Attenuates Contrast-induced Acute Kidney Injury.
Basic & clinical pharmacology & toxicology.
2018 Feb; 122(2):278-287. doi:
10.1111/bcpt.12895. [PMID: 28929640] - Jiezhong Yu, Qingfang Gu, Yuqing Yan, Hongqiang Yu, Minfang Guo, Chunyun Liu, Guobin Song, Zhi Chai, Qing Wang, Baoguo Xiao, Hanting Zhang, Yuqiang Jiang, Cungen Ma. [Fasudil improves cognition of APP/PS1 transgenic mice via inhibiting the activation of microglia and shifting microglia phenotypes from M1 to M2].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2017 Dec; 33(12):1585-1593. doi:
. [PMID: 29382415] - Ziqing Gao, Weiping Zhu, Hua Zhang, Zhonghe Li, Tongxia Cui. The influence of fasudil on renal proximal tubular cell epithelial-mesenchymal transition induced by parathormone.
Renal failure.
2017 Nov; 39(1):575-581. doi:
10.1080/0886022x.2017.1349677. [PMID: 28741985] - Yumi Kangawa, Toshinori Yoshida, Yutaka Yonezawa, Kiyoshi Maruyama, Shim-Mo Hayashi, Makoto Shibutani. Suppression of epithelial restitution using an inhibitor against Rho-associated coiled-coil containing protein kinase aggravates colitis through reduced epithelial expression of A-kinase anchor protein 13.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
2017 Oct; 69(8):557-563. doi:
10.1016/j.etp.2017.05.001. [PMID: 28535907] - Yan-Hua Li, Jing-Wen Yu, Jian-Yin Xi, Wen-Bo Yu, Jian-Chun Liu, Qing Wang, Li-Juan Song, Ling Feng, Ya-Ping Yan, Guang-Xian Zhang, Bao-Guo Xiao, Cun-Gen Ma. Fasudil Enhances Therapeutic Efficacy of Neural Stem Cells in the Mouse Model of MPTP-Induced Parkinson's Disease.
Molecular neurobiology.
2017 09; 54(7):5400-5413. doi:
10.1007/s12035-016-0027-8. [PMID: 27590141] - Keiichiro Matoba, Daiji Kawanami, Yosuke Nagai, Yusuke Takeda, Tomoyo Akamine, Sho Ishizawa, Yasushi Kanazawa, Tamotsu Yokota, Kazunori Utsunomiya. Rho-Kinase Blockade Attenuates Podocyte Apoptosis by Inhibiting the Notch Signaling Pathway in Diabetic Nephropathy.
International journal of molecular sciences.
2017 Aug; 18(8):. doi:
10.3390/ijms18081795. [PMID: 28820432] - Nibrass Taher Abdali, Awny H Yaseen, Eman Said, Tarek M Ibrahim. Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.
Naunyn-Schmiedeberg's archives of pharmacology.
2017 Apr; 390(4):409-422. doi:
10.1007/s00210-017-1343-x. [PMID: 28101628] - Mario J Aragon, Lauren Topper, Christina R Tyler, Bethany Sanchez, Katherine Zychowski, Tamara Young, Guy Herbert, Pamela Hall, Aaron Erdely, Tracy Eye, Lindsey Bishop, Samantha A Saunders, Pretal P Muldoon, Andrew K Ottens, Matthew J Campen. Serum-borne bioactivity caused by pulmonary multiwalled carbon nanotubes induces neuroinflammation via blood-brain barrier impairment.
Proceedings of the National Academy of Sciences of the United States of America.
2017 03; 114(10):E1968-E1976. doi:
10.1073/pnas.1616070114. [PMID: 28223486] - Shuang Chu, Xiaodong Mao, Hengjiang Guo, Li Wang, Zezheng Li, Yang Zhang, Yunman Wang, Hao Wang, Xuemei Zhang, Wen Peng. Indoxyl sulfate potentiates endothelial dysfunction via reciprocal role for reactive oxygen species and RhoA/ROCK signaling in 5/6 nephrectomized rats.
Free radical research.
2017 Mar; 51(3):237-252. doi:
10.1080/10715762.2017.1296575. [PMID: 28277985] - Jialing Rao, Zengchun Ye, Hua Tang, Cheng Wang, Hui Peng, Weiyan Lai, Yin Li, Wanbing Huang, Tanqi Lou. The RhoA/ROCK Pathway Ameliorates Adhesion and Inflammatory Infiltration Induced by AGEs in Glomerular Endothelial Cells.
Scientific reports.
2017 01; 7(?):39727. doi:
10.1038/srep39727. [PMID: 28054559] - Jing-Wen Yu, Yan-Hua Li, Guo-Bin Song, Jie-Zhong Yu, Chun-Yun Liu, Jian-Chun Liu, Hai-Fei Zhang, Wan-Fang Yang, Qing Wang, Ya-Ping Yan, Bao-Guo Xiao, Cun-Gen Ma. Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis.
Journal of molecular neuroscience : MN.
2016 Dec; 60(4):486-497. doi:
10.1007/s12031-016-0819-3. [PMID: 27573128] - Wenning Li, Wen Chen, Maowei Xie, Haiyang Huang, Huiluan Su, Hui Han, Daofa Zhang, Ying Zhang, Xiaohong Yang, Wentan Xu, Yan Su, Wei Wu, Yun Huang, Keying Fu, Jiali Wei. Fasudil inhibits tissue factor and plasminogen activator Inhibitor-1 secretion by peripheral blood mononuclear cells in CAPD patients.
Renal failure.
2016 Oct; 38(9):1359-1363. doi:
10.1080/0886022x.2016.1214053. [PMID: 27756191] - Heng Li, Min Zhang, Cong-Cong Wang, Xiao-Li Li, Peng Zhang, Long-Tao Yue, Shuai Miao, Ying-Chun Dou, Yan-Bin Li, Rui-Sheng Duan. ROCK inhibitor abolishes the antibody response in experimental autoimmune myasthenia gravis.
Molecular and cellular neurosciences.
2016 07; 74(?):106-13. doi:
10.1016/j.mcn.2016.05.001. [PMID: 27168379] - Xianyong Yu, Bingfei Jiang, Caifang Xun, Qing Yao. Interaction between fasudil hydrochloride and bovine serum albumin: spectroscopic study.
Luminescence : the journal of biological and chemical luminescence.
2016 Jun; 31(4):986-91. doi:
10.1002/bio.3062. [PMID: 26554343] - Chunyun Liu, Shangde Guo, Nianping Zhang, Jiezhong Yu, Baoguo Xiao, Cungen Ma. [Immunoregulative effect of Fasudil on encephalomyelitic T cells in experimental autoimmune encephalomyelitis mice].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.
2016 Mar; 41(3):225-32. doi:
10.11817/j.issn.1672-7347.2016.03.001. [PMID: 27033784] - Jie-Zhong Yu, Chan Chen, Qiong Zhang, Yong-Fei Zhao, Ling Feng, Hai-Fei Zhang, Jian Meng, Cun-Gen Ma, Bao-Guo Xiao. Changes of synapses in experimental autoimmune encephalomyelitis by using Fasudil.
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
2016 03; 24(2):317-27. doi:
10.1111/wrr.12407. [PMID: 26789651] - Lorenzo A Calò, Ugo Vertolli, Elisa Pagnin, Verdiana Ravarotto, Paul A Davis, Mario Lupia, Elena Naso, Giuseppe Maiolino, Agostino Naso. Increased rho kinase activity in mononuclear cells of dialysis and stage 3-4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications.
Life sciences.
2016 Mar; 148(?):80-5. doi:
10.1016/j.lfs.2016.02.019. [PMID: 26872982] - Hui Peng, Yuanqing Li, Cheng Wang, Jun Zhang, Yanru Chen, Wenfang Chen, Jin Cao, Yanlin Wang, Zhaoyong Hu, Tanqi Lou. ROCK1 Induces Endothelial-to-Mesenchymal Transition in Glomeruli to Aggravate Albuminuria in Diabetic Nephropathy.
Scientific reports.
2016 Feb; 6(?):20304. doi:
10.1038/srep20304. [PMID: 26842599] - Yihua Bei, Thong Hua-Huy, Carole Nicco, Sy Duong-Quy, Nhat-Nam Le-Dong, Kiet-Phong Tiev, Christiane Chéreau, Frédéric Batteux, Anh Tuan Dinh-Xuan. RhoA/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis.
Experimental lung research.
2016; 42(1):44-55. doi:
10.3109/01902148.2016.1141263. [PMID: 26873329] - Qing He, Yan-hua Li, Si-si Guo, Ying Wang, Wei Lin, Qiong Zhang, Jian Wang, Cun-gen Ma, Bao-Guo Xiao. Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
The European journal of neuroscience.
2016 Jan; 43(1):41-52. doi:
10.1111/ejn.13132. [PMID: 26565388] - Itsuko Baba, Yasuhiro Egi, Hiroyuki Utsumi, Tetsuhiro Kakimoto, Kazuo Suzuki. Inhibitory effects of fasudil on renal interstitial fibrosis induced by unilateral ureteral obstruction.
Molecular medicine reports.
2015 Dec; 12(6):8010-20. doi:
10.3892/mmr.2015.4467. [PMID: 26498136] - Chan Chen, Jie-Zhong Yu, Qiong Zhang, Yong-Fei Zhao, Chun-Yun Liu, Yan-Hua Li, Wan-Fang Yang, Cun-Gen Ma, Bao-Guo Xiao. Role of Rho Kinase and Fasudil on Synaptic Plasticity in Multiple Sclerosis.
Neuromolecular medicine.
2015 Dec; 17(4):454-65. doi:
10.1007/s12017-015-8374-6. [PMID: 26481340] - Guobin Song, Guoping Xi, Jiezhong Yu, Ling Feng, Jianjun Huang, Baoguo Xiao, Yanhua Li, Cungen Ma. [Promoting effect of Fasudil on the proliferation and survival of bone marrow-derived neural stem cells in vitro].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2015 Nov; 31(11):1488-91, 1496. doi:
NULL. [PMID: 26522357] - Fatma Aydinoglu, Olcay Ergurhan Kiroglu, Erhan Astarci, Ebru Balli, Nuran Ogulener. Effects of ethanol on RhoA/Rho-kinase-mediated calcium sensitization in mouse lung parenchymal tissue.
European journal of pharmacology.
2015 Oct; 764(?):318-327. doi:
10.1016/j.ejphar.2015.07.021. [PMID: 26169563] - Yan-hua Li, Jie-zhong Yu, Yan-le Xin, Ling Feng, Zhi Chai, Jian-chun Liu, Hong-zhen Zhang, Guang-Xian Zhang, Bao-guo Xiao, Cun-gen Ma. Protective effect of a novel Rho kinase inhibitor WAR-5 in experimental autoimmune encephalomyelitis by modulating inflammatory response and neurotrophic factors.
Experimental and molecular pathology.
2015 Oct; 99(2):220-8. doi:
10.1016/j.yexmp.2015.06.016. [PMID: 26112093] - Yan-Le Xin, Jie-Zhong Yu, Xin-Wang Yang, Chun-Yun Liu, Yan-Hua Li, Ling Feng, Zhi Chai, Wan-Fang Yang, Qing Wang, Wei-Jia Jiang, Guang-Xian Zhang, Bao-Guo Xiao, Cun-Gen Ma. FSD-C10: A more promising novel ROCK inhibitor than Fasudil for treatment of CNS autoimmunity.
Bioscience reports.
2015 07; 35(5):. doi:
10.1042/bsr20150032. [PMID: 26223433] - Jing Jin, Chao Peng, Su-zhen Wu, Hong-min Chen, Bai-fang Zhang. Blocking VEGF/Caveolin-1 signaling contributes to renal protection of fasudil in streptozotocin-induced diabetic rats.
Acta pharmacologica Sinica.
2015 Jul; 36(7):831-40. doi:
10.1038/aps.2015.23. [PMID: 25937636] - Zhiming Li, Hua Lian, Qin Liang, Fanfang Zeng, Dongdan Zheng. Effects of rosuvastatin combined with fasudil therapy on rabbits with dyslipidemia.
Lipids in health and disease.
2015 May; 14(?):52. doi:
10.1186/s12944-015-0050-1. [PMID: 26018523] - Yuji Nozaki, Koji Kinoshita, Shoichi Hino, Tomohiro Yano, Kaoru Niki, Yasuaki Hirooka, Kazuya Kishimoto, Masanori Funauchi, Itaru Matsumura. Signaling Rho-kinase mediates inflammation and apoptosis in T cells and renal tubules in cisplatin nephrotoxicity.
American journal of physiology. Renal physiology.
2015 Apr; 308(8):F899-909. doi:
10.1152/ajprenal.00362.2014. [PMID: 25651561] - Haiyan Hu, Wei Chen, Jiarong Ding, Meng Jia, Jingjing Yin, Zhiyong Guo. Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice.
Experimental and molecular pathology.
2015 Apr; 98(2):277-85. doi:
10.1016/j.yexmp.2015.02.006. [PMID: 25697583] - Noriaki Satoh, Yumiko Toyohira, Keita Takahashi, Nobuyuki Yanagihara. Effects of various pharmacological agents on the function of norepinephrine transporter.
Journal of UOEH.
2015 Mar; 37(1):33-42. doi:
10.7888/juoeh.37.33. [PMID: 25787100] - Tao Li, Guang-ming Yang, Yu Zhu, Yue Wu, Xiang-yun Chen, Dan Lan, Kun-lun Tian, Liang-ming Liu. Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
American journal of physiology. Endocrinology and metabolism.
2015 Feb; 308(4):E257-69. doi:
10.1152/ajpendo.00348.2014. [PMID: 25425000] - Carmen Kirchner, Bastian Lüer, Patrik Efferz, Jeremias Wohlschlaeger, Andreas Paul, Thomas Minor. Ex vivo use of a Rho-kinase inhibitor during renal preservation improves graft function upon reperfusion.
Cryobiology.
2015 Feb; 70(1):71-5. doi:
10.1016/j.cryobiol.2014.12.008. [PMID: 25555715] - Zhen Jia, Ashley C Johnson, Xuexiang Wang, Zibiao Guo, Albert W Dreisbach, Jack R Lewin, Patrick B Kyle, Michael R Garrett. Allelic Variants in Arhgef11 via the Rho-Rock Pathway Are Linked to Epithelial-Mesenchymal Transition and Contributes to Kidney Injury in the Dahl Salt-Sensitive Rat.
PloS one.
2015; 10(7):e0132553. doi:
10.1371/journal.pone.0132553. [PMID: 26172442] - Yong-fei Zhao, Qiong Zhang, Jian-ying Xi, Yan-hua Li, Cun-gen Ma, Bao-guo Xiao. Multitarget intervention of Fasudil in the neuroprotection of dopaminergic neurons in MPTP-mouse model of Parkinson's disease.
Journal of the neurological sciences.
2015; 353(1-2):28-37. doi:
10.1016/j.jns.2015.03.022. [PMID: 25908255] - Yongfei Zhao, Qiong Zhang, Jianying Xi, Baoguo Xiao, Yanhua Li, Cungen Ma. Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
International journal of clinical and experimental pathology.
2015; 8(3):2354-64. doi:
. [PMID: 26045742] - Chan Chen, Yan-hua Li, Qiong Zhang, Jie-zhong Yu, Yong-fei Zhao, Cun-gen Ma, Bao-guo Xiao. Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis.
Acta pharmacologica Sinica.
2014 Nov; 35(11):1428-38. doi:
10.1038/aps.2014.68. [PMID: 25263338] - GuiFang Guo, Vandana Singh, Douglas W Zochodne. Growth and turning properties of adult glial cell-derived neurotrophic factor coreceptor α1 nonpeptidergic sensory neurons.
Journal of neuropathology and experimental neurology.
2014 Sep; 73(9):820-36. doi:
10.1097/nen.0000000000000101. [PMID: 25101700] - Min-Fang Guo, Jian Meng, Yan-Hua Li, Jie-Zhong Yu, Chun-Yun Liu, Ling Feng, Wan-Fang Yang, Jun-Lian Li, Qian-Jin Feng, Bao-Guo Xiao, Cun-Gen Ma. The inhibition of Rho kinase blocks cell migration and accumulation possibly by challenging inflammatory cytokines and chemokines on astrocytes.
Journal of the neurological sciences.
2014 Aug; 343(1-2):69-75. doi:
10.1016/j.jns.2014.05.034. [PMID: 24952673] - Lars Tatenhorst, Lars Tönges, Kim-Ann Saal, Jan C Koch, Éva M Szegő, Mathias Bähr, Paul Lingor. Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Journal of neuropathology and experimental neurology.
2014 Aug; 73(8):770-9. doi:
10.1097/nen.0000000000000095. [PMID: 25003236] - Takuro Kobori, Shinichi Harada, Kazuo Nakamoto, Shogo Tokuyama. Involvement of PtdIns(4,5)P2 in the regulatory mechanism of small intestinal P-glycoprotein expression.
Journal of pharmaceutical sciences.
2014 Feb; 103(2):743-51. doi:
10.1002/jps.23811. [PMID: 24311454] - Magdalena Jasińska-Stroschein, Jacek Owczarek, Paulina Plichta, Daria Orszulak-Michalak. Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Pharmacology.
2014; 93(3-4):145-50. doi:
10.1159/000360182. [PMID: 24662671] - Yanhua Li, Xingwang Yang, Hui Zhang, Jiezhong Yu, Chunyun Liu, Ling Feng, Junlian Li, Baoguo Xiao, Cungen Ma. [Inhibition of Fasudil on lipopolysaccharide-induced TNF-α and IL-1β expressions through TLR4 pathway in murine BV-2 cells in vitro].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology.
2014 Jan; 30(1):11-4. doi:
". [PMID: 24405591] - Koichiro Homma, Koichi Hayashi, Shu Wakino, Hirobumi Tokuyama, Takeshi Kanda, Satoru Tatematsu, Kazuhiro Hasegawa, Seitaro Fujishima, Shingo Hori, Takao Saruta, Hiroshi Itoh. Rho-kinase contributes to pressure-induced constriction of renal microvessels.
The Keio journal of medicine.
2014; 63(1):1-12. doi:
10.2302/kjm.2013-0001-oa. [PMID: 24429483] - Keiichiro Matoba, Daiji Kawanami, Rina Okada, Masami Tsukamoto, Jun Kinoshita, Tomoko Ito, Sho Ishizawa, Yasushi Kanazawa, Tamotsu Yokota, Noriyuki Murai, Senya Matsufuji, Junko Takahashi-Fujigasaki, Kazunori Utsunomiya. Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
Kidney international.
2013 Sep; 84(3):545-54. doi:
10.1038/ki.2013.130. [PMID: 23615507] - James T Pearson, Mathew J Jenkins, Amanda J Edgley, Takashi Sonobe, Mandar Joshi, Mark T Waddingham, Yutaka Fujii, Daryl O Schwenke, Hirotsugu Tsuchimochi, Misa Yoshimoto, Keiji Umetani, Darren J Kelly, Mikiyasu Shirai. Acute Rho-kinase inhibition improves coronary dysfunction in vivo, in the early diabetic microcirculation.
Cardiovascular diabetology.
2013 Aug; 12(?):111. doi:
10.1186/1475-2840-12-111. [PMID: 24059472] - Taketoshi Kushiyama, Takashi Oda, Kojiro Yamamoto, Keishi Higashi, Atsushi Watanabe, Hanako Takechi, Takahiro Uchida, Naoki Oshima, Yutaka Sakurai, Soichiro Miura, Hiroo Kumagai. Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease.
American journal of physiology. Renal physiology.
2013 Jun; 304(11):F1325-34. doi:
10.1152/ajprenal.00447.2012. [PMID: 23552860] - Vivek Gupta, Nilesh Gupta, Imam H Shaik, Reza Mehvar, Ivan F McMurtry, Masahiko Oka, Eva Nozik-Grayck, Masanobu Komatsu, Fakhrul Ahsan. Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.
Journal of controlled release : official journal of the Controlled Release Society.
2013 Apr; 167(2):189-99. doi:
10.1016/j.jconrel.2013.01.011. [PMID: 23353807] - Norma B Ojeda, Thomas P Royals, Barbara T Alexander. Sex differences in the enhanced responsiveness to acute angiotensin II in growth-restricted rats: role of fasudil, a Rho kinase inhibitor.
American journal of physiology. Renal physiology.
2013 Apr; 304(7):F900-7. doi:
10.1152/ajprenal.00687.2012. [PMID: 23344570] - Satoshi Ikemura, Takuaki Yamamoto, Goro Motomura, Ryosuke Yamaguchi, Garida Zhao, Kenyu Iwasaki, Yukihide Iwamoto. Preventive effects of the anti-vasospasm agent via the regulation of the Rho-kinase pathway on the development of steroid-induced osteonecrosis in rabbits.
Bone.
2013 Apr; 53(2):329-35. doi:
10.1016/j.bone.2012.12.050. [PMID: 23313282] - Takuro Kobori, Shinichi Harada, Kazuo Nakamoto, Shogo Tokuyama. Activation of ERM-family proteins via RhoA-ROCK signaling increases intestinal P-gp expression and leads to attenuation of oral morphine analgesia.
Journal of pharmaceutical sciences.
2013 Mar; 102(3):1095-105. doi:
10.1002/jps.23441. [PMID: 23303573] - Yoshihiro Fukumoto, Norikazu Yamada, Hiromi Matsubara, Minori Mizoguchi, Kazuaki Uchino, Atsushi Yao, Yasuki Kihara, Mitsuhiro Kawano, Hiroshi Watanabe, Yutaka Takeda, Takeshi Adachi, Shinobu Osanai, Nobuhiro Tanabe, Teruo Inoue, Akihiro Kubo, Yuri Ota, Koichiro Fukuda, Takeshi Nakano, Hiroaki Shimokawa. Double-blind, placebo-controlled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension.
Circulation journal : official journal of the Japanese Circulation Society.
2013; 77(10):2619-25. doi:
10.1253/circj.cj-13-0443. [PMID: 23912836] - Magdalena Jasińska-Stroschein, Jacek Owczarek, Anna Łuczak, Daria Orszulak-Michalak. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Pharmacology.
2013; 91(3-4):178-84. doi:
10.1159/000346921. [PMID: 23428587] - Ying-Ying Yang, Yi-Tsau Huang, Tzung-Yan Lee, Che-Chang Chan, Yi-Chen Yeh, Kuei-Chuan Lee, Han-Chieh Lin. Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
2012 Nov; 18(11):1371-83. doi:
10.1002/lt.23520. [PMID: 22847887] - Kensuke Suzuki, Kayo Nemoto, Norifumi Ninomiya, Masamune Kuno, Minoru Kubota, Hiroyuki Yokota. Fasudil, a Rho-kinase inhibitor, attenuates lipopolysaccharide-induced vascular hyperpermeability and colonic muscle relaxation in guinea pigs.
The Journal of surgical research.
2012 Nov; 178(1):352-7. doi:
10.1016/j.jss.2012.01.043. [PMID: 22487385] - Jan M Williams, Ashley C Johnson, Cary Stelloh, Albert W Dreisbach, Nora Franceschini, Kevin R Regner, Raymond R Townsend, Richard J Roman, Michael R Garrett. Genetic variants in Arhgef11 are associated with kidney injury in the Dahl salt-sensitive rat.
Hypertension (Dallas, Tex. : 1979).
2012 Nov; 60(5):1157-68. doi:
10.1161/hypertensionaha.112.199240. [PMID: 22987919] - Gaia Novarino, Paul El-Fishawy, Hulya Kayserili, Nagwa A Meguid, Eric M Scott, Jana Schroth, Jennifer L Silhavy, Majdi Kara, Rehab O Khalil, Tawfeg Ben-Omran, A Gulhan Ercan-Sencicek, Adel F Hashish, Stephan J Sanders, Abha R Gupta, Hebatalla S Hashem, Dietrich Matern, Stacey Gabriel, Larry Sweetman, Yasmeen Rahimi, Robert A Harris, Matthew W State, Joseph G Gleeson. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy.
Science (New York, N.Y.).
2012 Oct; 338(6105):394-7. doi:
10.1126/science.1224631. [PMID: 22956686] - Noriaki Satoh, Yumiko Toyohira, Hideaki Itoh, Han Zhang, Susumu Ueno, Masato Tsutsui, Kojiro Takahashi, Nobuyuki Yanagihara. Stimulation of norepinephrine transporter function by fasudil, a Rho kinase inhibitor, in cultured bovine adrenal medullary cells.
Naunyn-Schmiedeberg's archives of pharmacology.
2012 Sep; 385(9):921-31. doi:
10.1007/s00210-012-0773-8. [PMID: 22752240] - Alan K Lam, Pamuditha N Silva, Svetlana M Altamentova, Jonathan V Rocheleau. Quantitative imaging of electron transfer flavoprotein autofluorescence reveals the dynamics of lipid partitioning in living pancreatic islets.
Integrative biology : quantitative biosciences from nano to macro.
2012 Aug; 4(8):838-46. doi:
10.1039/c2ib20075a. [PMID: 22733276]
